9 results on '"Pedrana, Alisa"'
Search Results
2. Evaluation of a Project Integrating Financial Incentives into a Hepatitis C Testing and Treatment Model of Care at a Sexual Health Service in Cairns, Australia, 2020–2021.
- Author
-
Dawe, Joshua, Gorton, Carla, Lewis, Rhondda, Richmond, Jacqueline A., Wilkinson, Anna L., Pedrana, Alisa, Stoové, Mark, Doyle, Joseph S., and Russell, Darren
- Subjects
HEPATITIS C ,MONETARY incentives ,MEDICAL care ,MEDICAL quality control ,PROJECT evaluation - Abstract
Background: Understanding the effectiveness of novel models of care in community-based settings is critical to achieving hepatitis C elimination. We conducted an evaluation of a hepatitis C model of care with financial incentives that aimed to improve engagement across the hepatitis C cascade of care at a sexual health service in Cairns, Australia. Methods: Between March 2020 and May 2021, financial incentives were embedded into an established person-centred hepatitis C model of care at Cairns Sexual Health Service. Clients of the Service who self-reported experiences of injecting drugs were offered an AUD 20 cash incentive for hepatitis C testing, treatment initiation, treatment completion, and test for cure. Descriptive statistics were used to describe retention in hepatitis C care in the incentivised model. They were compared to the standard of care offered in the 11 months prior to intervention. Results: A total of 121 clients received financial incentives for hepatitis C testing (antibody or RNA). Twenty-eight clients were hepatitis C RNA positive, of whom 92% (24/28) commenced treatment, 75% (21/28) completed treatment, and 68% (19/28) achieved a sustained virological response (SVR). There were improvements in the proportion of clients diagnosed with hepatitis C who commenced treatment (86% vs. 75%), completed treatment (75% vs. 40%), and achieved SVR (68% vs. 17%) compared to the pre-intervention comparison period. Conclusions: In this study, financial incentives improved engagement and retention in hepatitis C care for people who inject drugs in a model of care that incorporated a person-centred and flexible approach. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Impact of COVID-19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugs.
- Author
-
Traeger, Michael W., van Santen, Daniela K., Sacks-Davis, Rachel, Asselin, Jason, Carter, Allison, Doyle, Joseph S., Pedrana, Alisa, Wilkinson, Anna L., Howell, Jessica, Thatcher, Rebecca, Didlick, John, Donovan, Basil, Guy, Rebecca, Hellard, Margaret E., and Stoové, Mark A.
- Subjects
STAY-at-home orders ,HEPATITIS C ,CARE of people ,PRIMARY care ,ANTIBODY titer - Abstract
In 2020, the Australian state of Victoria experienced the longest COVID- 19 lockdowns of any jurisdiction, with two lockdowns starting in March and July, respectively. Lockdowns may impact progress towards eliminating hepatitis C through reductions in hepatitis C testing. To examine the impact of lockdowns on hepatitis C testing in Victoria, de-identified data were extracted from a network of 11 services that specialize in the care of people who inject drugs (PWID). Interrupted time-series analyses estimated weekly changes in hepatitis C antibody and RNA testing from 1 January 2019 to 14 May 2021 and described temporal changes in testing associated with lockdowns. Interruptions were defined at the weeks corresponding to the start of the first lockdown (week 14) and the start (week 80) and end (week 95) of the second lockdown. Pre-COVID, an average of 80.6 antibody and 25.7 RNA tests were performed each week. Following the first lockdown in Victoria, there was an immediate drop of 23.2 antibody tests and 8.6 RNA tests per week (equivalent to a 31% and 46% drop, respectively). Following the second lockdown, there was an immediate drop of 17.2 antibody tests and 4.6 RNA tests per week (equivalent to a 26% and 33% drop, respectively). With testing and case finding identified as a key challenge to Australia achieving hepatitis C elimination targets, the cumulative number of testing opportunities missed during lockdowns may prolong efforts to find, diagnose and engage or reengage in care of the remaining population of PWID living with hepatitis C. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019.
- Author
-
Lee Wilkinson, Anna, Pedrana, Alisa, Traeger, Michael W., Asselin, Jason, El-Hayek, Carol, Nguyen, Long, Polkinghorne, Victoria, Doyle, Joseph S., Thompson, Alexander J., Howell, Jessica, Scott, Nick, Dimech, Wayne, Guy, Rebecca, Hellard, Margaret, and Stoové, Mark
- Abstract
To achieve the elimination of the hepatitis C virus (HCV), sustained and sufficient levels of HCV testing is critical. The purpose of this study was to assess trends in testing and evaluate the effectiveness of strategies to diagnose people living with HCV. Data were from 12 primary care clinics in Victoria, Australia, that provide targeted services to people who inject drugs (PWID), alongside general health care. This ecological study spanned 2009–2019 and included analyses of trends in annual numbers of HCV antibody tests among individuals with no previous positive HCV antibody test recorded and annual test yield (positive HCV antibody tests/all HCV antibody tests). Generalised linear models estimated the association between count outcomes (HCV antibody tests and positive HCV antibody tests) and time, and χ
2 test assessed the trend in test yield. A total of 44 889 HCV antibody tests were conducted 2009–2019; test numbers increased 6% annually on average [95% confidence interval (CI) 4–9]. Test yield declined from 2009 (21%) to 2019 (9%) (χ2 P = <0.01). In more recent years (2013–2019) annual test yield remained relatively stable. Modest increases in HCV antibody testing and stable but high test yield within clinics delivering services to PWID highlights testing strategies are resulting in people are being diagnosed however further increases in the testing of people at risk of HCV or living with HCV may be needed to reach Australia's HCV elimination goals. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
5. Health service utilization and experiences of stigma amongst people who inject drugs in Melbourne, Australia.
- Author
-
Djordjevic, Filip, Ryan, Kathleen, Gunn, Jack, Brener, Loren, O'Keefe, Daniel, Draper, Bridget, Schroeder, Sophia, Gold, Judy, Treloar, Carla, Broady, Tim, Dietze, Paul, Hellard, Margaret, and Pedrana, Alisa
- Subjects
QUALITY of service ,SOCIAL stigma ,HEPATITIS C ,PROGRESSION-free survival - Abstract
Whilst the testing and treatment of people who inject drugs (PWID) in Australia is a priority for local hepatitis C (HCV) elimination efforts, perceived stigma related to injecting drug use (IDU) has been identified as a major barrier for PWID engaging in health services. We used data from the EC Experience cohort study to explore associations between IDU‐related perceived stigma and the number of different health services accessed by PWID in Melbourne, Australia. Data from the baseline questionnaire were used. Primary outcome was self‐reported experience of stigma due to IDU (never, rarely, sometimes, often, always) in the previous 12 months. An ordinal logistic regression model assessed the association between stigma experienced and the number of different health services used (1–2, 3–4, 5–6, 7–10 different services) adjusted for recent IDU and key socio‐demographics. Between September 2018 and February 2020, 281 participants were recruited from four health services. Sixty‐nine per cent were male, median age was 42, 83% reported past‐month IDU, 34% had never tested/tested >12 months, 8% tested negative <12 months, 43% were HCV‐positive but not treated and 16% had been treated. Those accessing 5–6 services had 2.2 times greater odds of experiencing stigma (95% CI 0.86–6.65) compared with those using <5 services and those reporting 7–10 services had 2.43 times greater odds of experiencing stigma (95% CI 0.85–6.92) compared with those accessing <7 services. In conclusion, experiences of stigma may not necessarily be a barrier for PWID to access health services, but high rates of health service use may further expose, exacerbate or exaggerate stigma amongst PWID. Further examination of how stigma may be in/directly impact on hepatitis C treatment uptake is important and place‐based interventions aimed at reducing stigma experienced by PWID may be needed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Increasing hepatitis C testing and linkage to care: Results of a testing campaign with incentives at primary care clinics in Melbourne, Australia.
- Author
-
Chan, Kico, Elsum, Imogen, Gold, Judy, Layton, Chloe, Accadia, Lisa, Bryant, Mellissa, Gunn, Jack, Djordjevic, Filip, Purcell, Isabelle, Dicka, Jane, Forrest, Martin, Crawford, Sione, Hellard, Margaret, and Pedrana, Alisa
- Subjects
PRIMARY care ,COMMUNITY health services ,MEDICAL personnel ,HEPATITIS C ,NURSING informatics - Published
- 2021
- Full Text
- View/download PDF
7. A survey of Australian general practitioners' hepatitis C knowledge and management 2 years after subsidised direct-acting antiviral therapy became available.
- Author
-
Gooey, Michelle, Wong, Evelyn, Pedrana, Alisa, Allard, Nicole, Doyle, Joseph, Hellard, Margaret, and Wade, Amanda
- Subjects
HEPATITIS C ,GENERAL practitioners ,KNOWLEDGE management ,PRIMARY care ,HEPATITIS C prevention ,RESEARCH ,RESEARCH methodology ,ANTIVIRAL agents ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,HEALTH attitudes ,QUESTIONNAIRES - Abstract
In 2016, hepatitis C direct-acting antivirals (DAAs) became available in Australia. A group of general practitioners (GPs) were surveyed twice to assess hepatitis C knowledge and management; 191/1000 (19.1%) responded at baseline, 164/938 (17.5%) at follow up. Participants' mean Knowledge score increased: baseline 5.75 (95% CI 5.61-5.91), follow up 6.09 (95% CI 5.95-6.22; P <0.01). At follow up, 36/163 (22%) had prescribed DAAs compared with 23/187 (12%) at baseline (χ2(1) = 5.95, P = 0.02); however, 67/150 (45%) were unsure of treatment eligibility for people who inject drugs. Additional support for GPs is warranted to ensure optimal hepatitis C management in primary care. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Hepatitis C antibody testing among opioid agonist therapy recipients, Victoria, Australia, 2012 to 2020.
- Author
-
Dawe, Joshua, Wilkinson, Anna L., Asselin, Jason, Carter, Allison, Pedrana, Alisa, Traeger, Michael W., Thomas, Alexander J., Curtis, Michael, Cooper, Monica, Howell, Jessica, Doyle, Joseph S., Hellard, Margaret E., Stoové, Mark, and EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of blood borne viruses and sexually transmissible infections (ACCESS)
- Subjects
- *
HEPATITIS C diagnosis , *INTRAVENOUS drug abuse , *HEPATITIS C , *HEPATITIS viruses , *ANTIVIRAL agents , *OPIOID analgesics , *VIRAL antibodies , *DISEASE complications - Abstract
Background: The high burden of hepatitis C among people who inject drugs in Australia underscores the need to increase testing within this population. Understanding hepatitis C screening uptake in primary care settings is therefore critical to the development of effective and targeted strategies to improve hepatitis C testing for people who inject drugs. Primary care services that prescribe OAT are well-positioned to provide hepatitis C testing among a priority population at-risk of hepatitis C.Methods: This study used linked data from 5,429 individuals attending ten clinical services participating in the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS) who received their first recorded OAT prescription between 1st January 2012 and 31st December 2019. We estimated the proportion of OAT recipients who received a hepatitis C antibody test within 12 months of their first recorded OAT prescription, and the proportion of individuals tested who received a positive hepatitis C antibody test.Results: Approximately one in five individuals (17%) received a hepatitis C antibody test in the 12 months following their first recorded OAT prescription. Over half of individuals tested (56%) received a positive hepatitis C antibody test result. Hepatitis C antibody testing was higher among individuals who attended 5-8 (aOR:2.98; 95%CI:2.41-3.69) and 9+ (aOR:6.17; 95%CI:5.13-7.43) clinical consultations, were women (aOR:1.20; 95%CI:1.08-1.34) and whose first recorded OAT prescription occurred in 2017 vs. 2012 (aOR:1.39; 95%CI:1.06-1.84). Hepatitis C antibody testing was lower among individuals prescribed methadone (aOR:0.81; 95%CI:0.73-0.91), and individuals aged 60+ years vs. 18-29 years (aOR:0.67; 95%CI:0.48-0.94).Conclusion: Despite high positivity rates, hepatitis C antibody testing among individuals prescribed OAT remains low. There are opportunities for increased testing among populations exhibiting greater proportions of missed testing opportunities. Integrating routine hepatitis C screening in OAT settings will likely increase case-finding and contribute to Australia's hepatitis C elimination targets. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
9. Hepatitis C incidence among patients attending primary care health services that specialise in the care of people who inject drugs, Victoria, Australia, 2009 to 2020.
- Author
-
Wilkinson, Anna Lee, van Santen, Daniela K, Traeger, Michael W, Sacks-Davis, Rachel, Asselin, Jason, Scott, Nick, Harney, Brendan L, Doyle, Joseph S, El-Hayek, Carol, Howell, Jessica, Bramwell, Fran, McManus, Hamish, Donovan, Basil, Stoové, Mark, Hellard, Margaret, and Pedrana, Alisa
- Subjects
- *
HEPATITIS C treatment , *INTRAVENOUS drug abusers , *ANTIVIRAL agents , *DRUG therapy , *PRIMARY care , *CHRONIC hepatitis C , *INTRAVENOUS drug abuse , *HEPATITIS C , *MEDICAL care , *RNA , *HEPATITIS viruses , *DISEASE incidence , *PRIMARY health care , *VIRAL antibodies , *DRUG abusers - Abstract
Background: Monitoring trends in hepatitis C virus (HCV) incidence is critical for evaluating strategies aimed at eliminating HCV as a public health threat. We estimate HCV incidence and assess trends in incidence over time among primary care patients.Methods: Data were routinely extracted, linked electronic medical records from 12 primary care health services. Patients included were aged ≥16 years, tested HCV antibody negative on their first test recorded and had at least one subsequent HCV antibody or RNA test (January 2009-December 2020). HCV incident infections were defined as a positive HCV antibody or RNA test. A generalised linear model assessed the association between HCV incidence and calendar year.Results: In total, 6711 patients contributed 17,098 HCV test records, 210 incident HCV infections and 19,566 person-years; incidence was 1.1 per 100 person-years (95% confidence interval (CI): 0.9 to 1.2). Among 559 (8.2%) patients ever prescribed opioid-related pharmacotherapy (ORP) during the observation period, 135 infections occurred during 2,082 person-years (incidence rate of 6.5 per 100 person-years (95% CI: 5.4 to 7.7)). HCV incidence declined 2009-2020 overall (incidence rate ratio per calendar year 0.8 (95% CI: 0.8 to 0.9) and among patients ever prescribed ORT (incidence rate ratio per calendar year 0.9, 95% CI: 0.75 to 1.0).Conclusion: HCV incidence declined among patients at primary care health services including among patients ever prescribed ORP and during the period following increased access to DAA therapy. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.